

---

**Optimization of the GeneBLAzer® M5 NFAT-*bla* CHO-K1 Cell Line**

---

**GeneBLAzer® M5 CHO-K1 DA Assay Kit****GeneBLAzer® M5 NFAT-*bla* CHO-K1 Cells**

Catalog Numbers – K1351 and K1728

**Cell Line Descriptions**

GeneBLAzer® M5 CHO-K1 DA (Division Arrested) cells and GeneBLAzer® M5-NFAT-*bla* CHO-K1 cells contain the human Acetylcholine (muscarinic) subtype 5 (M5) receptor (Accession #BC041805.1) stably integrated into the CellSensor® NFAT-*bla* CHO-K1 cell line. CellSensor® NFAT-*bla* CHO-K1 cells (Cat. no. K1534) contain a beta-lactamase (*bla*) reporter gene under control of the Nuclear Factor of Activated T-cells (NFAT) response element. Division Arrested (DA) cells are available as an Assay Kit, which includes cells and sufficient substrate to analyze 1 x 384-well plate.

DA cells are irreversibly division arrested using a low-dose treatment of Mitomycin-C, and have no apparent toxicity or change in cellular signal transduction. Both GeneBLAzer® M5 CHO-K1 DA cells and GeneBLAzer® M5-NFAT-*bla* CHO-K1 cells are functionally validated for Z'-factor and EC<sub>50</sub> concentrations of carbachol (Figure 1). In addition, M5-NFAT-*bla* CHO-K1 cells have been tested for assay performance under variable conditions, including DMSO concentration, cell number, stimulation time, and substrate loading time. Additional testing data using alternate stimuli are also included.

**Target Description**

Muscarinic acetylcholine receptors are members of the G protein-coupled receptor (GPCR) superfamily. Muscarinic receptors are widely distributed and mediate the actions of acetylcholine in both the CNS and peripheral tissues. Five muscarinic receptor subtypes have been identified and are referred to as M<sub>1</sub>-M<sub>5</sub> (1-5).

The M<sub>1</sub>, M<sub>3</sub>, and M<sub>5</sub> receptor subtypes couple through the G<sub>q/11</sub> class of G-proteins and activate the phospholipase C pathway. Activation of this pathway in turn leads to increases in free intracellular calcium levels as inositol triphosphate mediates release of calcium from the endoplasmic reticulum. In addition, protein kinase C is activated via diacylglycerol. The M<sub>2</sub> and M<sub>4</sub> receptor subtypes couple through the G<sub>i/o</sub> class of G proteins and inhibit adenylyl cyclase activity.

The M<sub>5</sub> subtype is expressed in brain at very low levels with a limited distribution. The physiological relevance of this receptor subtype remains unknown, primarily because of its low expression levels and the lack of M<sub>5</sub> receptor-selective ligands. However, knockout studies have suggested that the role of M<sub>5</sub> involves modulation of central dopamine function and the tone of cerebral blood vessels (6-8). In addition, M<sub>5</sub> may be important in the treatment of addiction (8). Additional information on the muscarinic receptors can be found in reviews (9-12).

## Validation Summary

Performance of this assay was validated under optimized conditions in 384-well format using LiveBLAzer™-FRET B/G Substrate.

### 1. Carbachol agonist dose response under optimized conditions

	DA cells	Dividing Cells
EC <sub>50</sub>	0.5 μM	1.0 μM
Z'-factor	0.94	0.94

Optimum cell no.	= 10K cells/well
Optimum [DMSO]	= up to 1%
Optimum Stim. Time	= 3 hours
Max. [Stimulation]	= 30 μM

### 2. Alternate agonist dose response

Oxotremorine M EC <sub>50</sub>	= 193 nM
MCN-A-343 EC <sub>50</sub>	= 9.4 μM
Pilocarpine EC <sub>50</sub>	= 17 μM
Bethanecol EC <sub>50</sub>	= 25 μM

### 3. Antagonist dose response

Scopolamine IC <sub>50</sub>	= 2 nM
DAMP IC <sub>50</sub>	= 6 nM
Telenzipine IC <sub>50</sub>	= 23 nM
Methoctramine IC <sub>50</sub>	= 18 μM

### 4. Agonist Dose Response Using Fluo-4NW


Carbachol EC <sub>50</sub>	= 508 nM
----------------------------	----------

## Assay Testing Summary

- Assay performance with variable cell number
- Assay performance with variable stimulation time
- Assay performance with variable substrate loading time
- Assay performance with variable DMSO concentration

## Primary Agonist Dose Response


**Figure 1 — GeneBLAzer® M5 CHO-K1 DA and M5-NFAT-*bla* CHO-K1 dose response to carbachol under optimized conditions**



GeneBLAzer® M5 CHO-K1 DA cells and GeneBLAzer® M5-NFAT-*bla* CHO-K1 cells (10,000 cells/well) were plated in a 384-well format and incubated for 16-20 hours. Cells were stimulated with a dilution series of carbachol in the presence of 0.5% DMSO for 5 hours. Cells were then loaded with LiveBLAzer™-FRET B/G Substrate for 2 hours. Fluorescence emission values at 460 nm and 530 nm were obtained using a standard fluorescence plate reader and % Activation plotted for each replicate against the concentrations of carbachol (n=6 for each data point).

## Alternate Agonist Dose Response


**Figure 2 — GeneBLAzer® M5-NFAT-*bla* CHO-K1 dose response to Bethanecol, Oxotremorine M, MCN-A-343, Pilocarpine and Carbachol**



GeneBLAzer® M5-NFAT-*bla* CHO-K1 cells (20,000 cells/well) were plated the day of the assay in a 384-well format. Cells were stimulated with Carbachol (Sigma #21760), Bethanecol (Sigma #C5259), Oxotremorine (Sigma #O-100), MCN-A-343 (Sigma #C7041), or Pilocarpine (Sigma #P6503) over the indicated concentration range in the presence of 0.5% DMSO for 5 hours. Cells were then loaded with LiveBLAzer™-FRET B/G Substrate for 2 hours. Fluorescence emission values at 460 nm and 530 nm were obtained using a standard fluorescence plate reader and the % Activation shown plotted against the indicated concentrations of the agonists.

### Antagonist Dose Response


Figure 3 — GeneBLAzer® M5-NFAT-*bla* CHO-K1 dose response to Telenzipine, Scopolamine, DAMP and Methoctramine




GeneBLAzer® M5-NFAT-*bla* CHO-K1 cells (20,000 cells/well) were plated the day of the assay in a 384-well black-walled tissue culture assay plate. Cells were treated with the antagonists Telenzipine (T-122), Scopolamine (S1875), DAMP (D104) and Methoctramine (M-105) and incubated at 37 degrees C for 20 min., followed by 1.5  $\mu$ M Carbachol agonist stimulation for 5 hours in 0.5% DMSO. Cells were then loaded for 2 hours with LiveBLAzer™-FRET B/G Substrate. Fluorescence emission values at 460 nm and 530 nm were obtained using a standard fluorescence plate reader and the % Inhibition was plotted against the indicated concentrations of the antagonist. The data shows the correct rank order potency.

### Agonist Dose Response Using Fluo-4NW


Figure 4 — GeneBLAzer® M5-NFAT-*bla* CHO-K1 dose response to Carbachol using Fluo-4NW




GeneBLAzer® M5-NFAT-*bla* CHO-K1 cells (10,000 cells/well) were plated the day before the assay in a 384-well format. Cells were then incubated with Fluo-4NW for 30 min at 37°C, followed by 30 min. at room temperature. Cells were then stimulated with a dilution series of Carbachol (Sigma #21760) in the presence of 0.5% DMSO. Fluorescence emission values at 516 nm were obtained and the % Activation plotted against the indicated concentrations of carbachol (n=16 for each data point).

**Optimization of the GeneBLAzer® M5 NFAT-*bla* CHO-K1 Cell Line**
**Assay Performance with Variable Cell Number**
**Figure 5— GeneBLAzer® M5-NFAT-*bla* CHO-K1 dose response using 2.5, 5, 10, and 20K cells/well**



GeneBLAzer® M5-NFAT-*bla* CHO-K1 cells were plated at 2,500, 5000, 10,000 or 20,000 cells/well in a 384-well format. On the day of the assay, cells were stimulated with Carbachol (Sigma #21760) in the presence of 0.5% DMSO for 5 hours. Cells were then loaded with LiveBLAzer™-FRET B/G Substrate for 2 hours. Fluorescence emission values at 460 nm and 530 nm for the various cell numbers were obtained using a standard fluorescence plate reader and the Response Ratios plotted against the indicated concentrations of Carbachol (n=8 for each data point).

**Assay performance with Variable Stimulation Time**
**Figure 6 – GeneBLAzer® M5-NFAT-*bla* CHO-K1 dose response using 3, 4, and 5 hour stimulation times**


GeneBLAzer® M5-NFAT-*bla* CHO-K1 cells (20,000 cells/well) were plated the day of the assay in a 384-well black-walled tissue culture assay plate. Carbachol (Sigma #21760) was then added to the plate over the indicated concentration range for 3, 4, or 5 hrs in 0.5% DMSO and then loaded for 2 hours with LiveBLAzer™-FRET B/G Substrate. Fluorescence emission values at 460 nm and 530 nm were obtained using a standard fluorescence plate reader and the Response Ratios for each substrate loading time were plotted against the indicated concentrations of carbachol (n=8 for each data point)

**Assay performance with Variable Substrate Loading Time**
**Figure 7 – GeneBLAzer® M5-NFAT-*bla* CHO-K1 dose response using 1.5, 2, and 2.5 hr substrate loading times**


GeneBLAzer® M5-NFAT-*bla* CHO-K1 cells were plated at 20,000 cells/well in a 384-well format. On the day of the assay, cells were stimulated with Carbachol (Sigma #21760) in the presence of 0.5% DMSO for 5 hours. Cells were then loaded with LiveBLAzer™-FRET B/G Substrate for either 1.5, 2 or 2.5 hours. Fluorescence emission values at 460 nm and 530 nm for the various cell numbers were obtained using a standard fluorescence plate reader and the Response Ratios plotted against the indicated concentrations of Carbachol (n=8 for each data point).

**Assay Performance with variable DMSO concentration**
**Figure 8 – GeneBLAzer® M5-NFAT-*bla* CHO-K1 dose response using 0, 0.1, 0.5 and 1% DMSO.**


GeneBLAzer® M5-NFAT-*bla* CHO-K1 cells (10,000 cells/well) were plated the day of the assay in a 384-well black-walled tissue culture assay plate. Carbachol (Sigma #21760) was then added to the plate over the indicated concentration range. DMSO was added to the assay at concentrations from 0% to 1%. Cells were stimulated for 5 hrs with agonist and loaded for 2 hours with LiveBLAzer™-FRET B/G Substrate. Fluorescence emission values at 460 nm and 530 nm were obtained using a standard fluorescence plate reader and the Response Ratios are for each DMSO concentration were plotted against the indicated concentrations of carbachol (n=8 for each data point).

## References

1. Bonner, T. I., *et al.* (1987) **Identification of a family of muscarinic acetylcholine receptor genes.** *Science*, **237**, 527 - 532.
2. Bonner, T. I., *et al.* (1988) **Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes.** *Neuron*, **1**, 403 - 410.
3. Kubo, T. *et al.* (1986) **Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor.** *Nature*, **323**, 411 - 416.
4. Kubo, T. *et al.* (1986) **Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence.** *FEBS Lett.*, **209**, 367 - 372.
5. Peralta, E. G., *et al.* (1987) **Distinct primary structures, ligand binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors.** *EMBO J.*, **6**, 3923 - 3929.
6. Yeomans, J., Forster, G. and Blaha, C. (2001) **M5 muscarinic receptors are needed for slow activation of dopamine neurons and for rewarding brain stimulation.** *Life Sci.*, **68**, 2449-2456.
7. Bymaster, F.P., McKinzie, D.L., Felder, C.C. and Wess, J. (2003) **Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system.** *Neurochem Res.*, **28**, 437-442.
8. Yang, G. (2002) **Muscarinic receptors: a novel therapeutic target for drug addiction.** *Trends Pharmacol Sci.*, **23**, 551.
9. Caulfield, M. P. and Birdsall, N. J. M. (1998) **International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.** *Pharmacol. Rev.*, **50**, 279 - 290.
10. Caulfield, M.P. (1993) **Muscarinic receptors characterization, coupling and function.** *Pharmacol. Ther.*, **58**, 319 - 379.
11. Eglen, R. M., Hegde, S. S. and Watson, N. (1996) **Muscarinic receptor subtypes and smooth muscle function.** *Pharmacol. Rev.*, **48**, 531 - 565.
12. Hulme, E. C., Birdsall, N. J. M. and Buckley, N. J. (1990) **Muscarinic receptor subtypes.** *Annu. Rev. Pharmacol. Toxicol.*, **30**, 633 - 673.